Reason for request
Inclusion on list of products reimbursed by National Insurance and for hospital use.
Clinical Benefit
| Substantial |
The actual benefit of FIRMAGON is substantial. |
Clinical Added Value
| no clinical added value |
In the context of the current strategy for treatment of advanced prostate cancer, with a combination of a Gn-RH analogue and an antiandrogen in the first month of treatment, FIRMAGON provides no improvement in actual benefit (IAB level V). |
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
nLZAkAuNcdp9KGdk
